Resona Asset Management Co. Ltd. Has $4.84 Million Holdings in The Cooper Companies, Inc. $COO

Resona Asset Management Co. Ltd. grew its position in The Cooper Companies, Inc. (NASDAQ:COO) by 7.9% in the second quarter, according to its most recent filing with the SEC. The fund owned 67,988 shares of the medical device company’s stock after acquiring an additional 4,976 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Cooper Companies were worth $4,838,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Zions Bancorporation National Association UT bought a new position in Cooper Companies in the first quarter valued at about $33,000. GKV Capital Management Co. Inc. bought a new stake in shares of Cooper Companies during the first quarter worth about $40,000. J.Safra Asset Management Corp increased its stake in shares of Cooper Companies by 204.8% in the second quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock valued at $36,000 after buying an additional 340 shares during the period. Assetmark Inc. raised its holdings in Cooper Companies by 357.8% in the 2nd quarter. Assetmark Inc. now owns 618 shares of the medical device company’s stock valued at $44,000 after buying an additional 483 shares during the last quarter. Finally, Larson Financial Group LLC boosted its position in Cooper Companies by 1,071.0% during the 1st quarter. Larson Financial Group LLC now owns 726 shares of the medical device company’s stock worth $61,000 after buying an additional 664 shares during the period. Institutional investors own 24.39% of the company’s stock.

Insider Buying and Selling at Cooper Companies

In other news, COO Daniel G. Mcbride purchased 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were bought at an average cost of $65.04 per share, with a total value of $195,120.00. Following the completion of the transaction, the chief operating officer directly owned 63,120 shares of the company’s stock, valued at approximately $4,105,324.80. This trade represents a 4.99% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Gerard H. Warner III purchased 1,450 shares of the business’s stock in a transaction that occurred on Friday, September 5th. The shares were purchased at an average price of $69.23 per share, for a total transaction of $100,383.50. Following the completion of the acquisition, the chief operating officer owned 18,319 shares of the company’s stock, valued at $1,268,224.37. The trade was a 8.60% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders purchased 17,975 shares of company stock worth $1,216,346. 1.98% of the stock is currently owned by insiders.

Cooper Companies Price Performance

COO stock opened at $70.10 on Monday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.24 and a current ratio of 2.12. The business has a 50-day simple moving average of $69.24 and a two-hundred day simple moving average of $72.59. The company has a market capitalization of $13.94 billion, a P/E ratio of 34.53, a price-to-earnings-growth ratio of 1.83 and a beta of 1.02. The Cooper Companies, Inc. has a 52-week low of $61.78 and a 52-week high of $106.63.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Wednesday, August 27th. The medical device company reported $1.10 earnings per share for the quarter, beating analysts’ consensus estimates of $1.07 by $0.03. The company had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The company’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter last year, the company earned $0.96 earnings per share. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. Research analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies declared that its board has approved a stock buyback program on Wednesday, September 17th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical device company to reacquire up to 15.4% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

Analysts Set New Price Targets

COO has been the subject of several recent research reports. BNP Paribas Exane upgraded shares of Cooper Companies from a “neutral” rating to an “outperform” rating and set a $92.00 price target for the company in a research report on Tuesday, July 22nd. Robert W. Baird cut their price target on Cooper Companies from $97.00 to $85.00 and set an “outperform” rating on the stock in a report on Thursday, August 28th. The Goldman Sachs Group set a $64.00 price target on shares of Cooper Companies and gave the stock a “sell” rating in a report on Wednesday, October 1st. Mizuho dropped their price objective on shares of Cooper Companies from $105.00 to $90.00 and set an “outperform” rating on the stock in a report on Wednesday, July 16th. Finally, Barclays assumed coverage on shares of Cooper Companies in a research report on Monday, October 13th. They set an “overweight” rating and a $85.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $84.77.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.